Shares of ICON plc (ICLR) plunged 14.28% in after-hours trading on Wednesday following the release of the company's third-quarter 2025 financial results and revised full-year guidance. The clinical research organization reported lower-than-expected earnings and recorded a significant goodwill impairment charge, sparking investor concerns about the company's near-term prospects.

ICON reported Q3 revenue of $2.04 billion, representing a slight increase of 0.6% compared to the same period last year. However, the company's GAAP net income for the quarter was just $2.4 million, or $0.03 per diluted share, a significant drop from the previous year. This substantial decline in profitability was largely attributed to a non-cash goodwill impairment charge of $165.3 million recorded for the Data Solutions Reporting Unit.

Adding to investor worries, ICON amended its full-year 2025 financial guidance. While the company increased its revenue forecast to a range of $8,050 - $8,100 million, it updated its adjusted diluted earnings per share guidance to a range of $13.00 - $13.20. CEO Barry Balfe acknowledged the challenging market conditions, citing "ongoing challenges in the sector including delayed decision making, elevated cancellations and uncertainty in the macro environment." These factors, combined with the impact of higher pass-through revenues, have led to the revised outlook, which appears to have disappointed investors and contributed to the sharp stock price decline.